title: A perfluorocarbon emulsion prime additive improves the electroencephalogram and cerebral blood flow at the initiation of cardiopulmonary bypass.
abstract: Depression in electroencephalogram (EEG) has been documented clinically and is reproducible in swine at the initiation of cardiopulmonary bypass (CPB) utilizing a crystalloid prime. The physiological cause of this transient alteration in electrical brain activity appears to be associated with the transient drop in arterial pressure. The etiology is unknown but may be attributable to the bolus of the crystalloid prime or micro emboli, either air or fibrin-platelet. Thirteen swine (17-26 kg) were anesthetized and received 4 mg/kg dexamethasone, and following a tracheotomy were ventilated with halothane in 100% O2. Surgical preparation included: sternotomy and preparation for right atrial-aortic CPB. The CPB circuit consisted of a hollow fiber membrane oxygenator, a hard-shell venous reservoir, a roller pump, and PVC tubing. The circuit was randomly primed with either 1200 ml Plasmalyte-A or 10 ml/kg perfluorocarbon emulsion (PFE) and Plasmalyte-A to total 1200 ml. The animals were monitored continuously for systemic hemodynamics and electrocardiogram, and cerebral monitoring included blood flow and bitemporal EEG. Arterial blood gases were measured and PaCO2 was kept between 30-45 mmHg both before and during CPB. Cerebral blood flow (CBF) was measured pre-CPB and at 10 minutes after initiation of CPB. Bitemporal computerized EEG was analyzed every 60 seconds. Total power of each hemisphere, power in frequency bands, and spectral edge were recorded. All animals demonstrated a relative decrease in EEG total power at the onset of CPB. Animals that received PFE demonstrated a more stable arterial blood pressure, an increased CBF, and a lesser decrease and an earlier recovery of the EEG power.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Surgery, School of Medicine, University of Washington, Seattle 98195, USA.
authors.forename: C
authors.initials: C
authors.lastname: Vocelka
authors.forename: B
authors.initials: B
authors.lastname: Spiess
authors.forename: L
authors.initials: L
authors.lastname: Soltow
authors.forename: R
authors.initials: R
authors.lastname: Thomas
authors.forename: H
authors.initials: H
authors.lastname: Gohra
authors.forename: H
authors.initials: H
authors.lastname: Akimoto
authors.forename: C
authors.initials: C
authors.lastname: Rothnie
authors.forename: K
authors.initials: K
authors.lastname: Kunzelman
authors.forename: E
authors.initials: E
authors.lastname: Verrier
authors.forename: R P
authors.initials: RP
authors.lastname: Cochran
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002315:Cardiopulmonary Bypass; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004569:Electroencephalography / Q000187:drug effects*; D004573:Electrolytes / Q000008:administration & dosage / Q000627:therapeutic use; D004655:Emulsions; D005466:Fluorocarbons / Q000008:administration & dosage / Q000494:pharmacology*; D008863:Microspheres; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000494:pharmacology; D010107:Oxygenators, Membrane; D010952:Plasma Substitutes / Q000008:administration & dosage / Q000627:therapeutic use; D012996:Solutions; D013552:Swine